INTRODUCTION

Obstructive pulmonary disease, encompassing chronic obstructive pulmonary disease (COPD) and asthma, is a significant global health issue characterized by progressive airflow limitation, respiratory symptoms, and impaired quality of life.\(^1\) It poses a substantial burden on individuals, healthcare systems, and society as a whole, with high morbidity and mortality rates.\(^2\) While the pathogenesis of obstructive pulmonary disease is multifactorial, including genetic predisposition and environmental factors, emerging evidence suggests that the lung microbiome may play a crucial role in disease development and progression.\(^3\)

The lung microbiome refers to the complex microbial communities residing within the respiratory tract. Previously, the lungs were considered sterile;
however, advances in culture-independent techniques have revealed the presence of diverse bacterial and fungal populations in healthy individuals. Disruptions in the microbial profiles, termed dysbiosis, have been associated with various respiratory diseases, including obstructive pulmonary disease. Several studies have examined the impact of microbial profiles on obstructive pulmonary disease, providing insights into their potential contributions to disease pathogenesis. Dysbiosis in the lung microbiome has been associated with airway inflammation, exacerbation frequency, disease severity, and treatment outcomes. However, most of these investigations have focused on specific patient populations or have been conducted in research settings, limiting the generalizability of the findings.

To address this gap in knowledge, the present observational study aimed to analyze the microbial profiles in patients with obstructive pulmonary disease at a tertiary care hospital. By examining a diverse patient population in a real-world clinical setting, we sought to provide valuable insights into the microbial composition and its associations with clinical parameters. Understanding the specific microbial profiles associated with obstructive pulmonary disease in a tertiary care setting can have important implications for disease management and personalized treatment approaches.

The findings from this study may help identify potential microbial markers for disease severity, exacerbation risk, and therapeutic response. Furthermore, this research contributes to the broader understanding of the lung microbiome's role in obstructive pulmonary disease and its potential as a target for novel therapeutic interventions.

This study aims to shed light on the microbial profiles in patients with obstructive pulmonary disease, focusing on a tertiary care hospital setting. By elucidating the associations between microbial composition and clinical parameters, we aim to enhance our understanding of disease pathogenesis and potentially pave the way for future personalized approaches in obstructive pulmonary disease management.

**MATERIALS AND METHODS**

**Study Design**

This study employed an observational design to analyze the microbial profiles in patients with obstructive pulmonary disease at Chalmeda Anand Rao Institute of Medical Sciences, Karimnagar, Telangana between June 2022 to May 2023.

**Participants:** Patients diagnosed with obstructive pulmonary disease, including COPD and asthma, were consecutively enrolled from Tertiary Care Hospital.

**Inclusion Criteria**

Patients diagnosed with obstructive pulmonary disease, including chronic obstructive pulmonary disease (COPD) and asthma.

- Age 18 years or older.
- Patients receiving treatment at the specific tertiary care hospital.
- Ability to provide informed consent.

**Exclusion Criteria**

Patients with a history of other significant respiratory diseases not related to obstructive pulmonary disease.

- Age below 18 years.
- Patients with significant comorbidities or conditions that could confound the study results.
- Patients unable to provide informed consent or participate in study procedures.

Informed consent was obtained from all participants.

**Data Collection**

Demographic data, including age, sex, and smoking history, were collected from each participant. Clinical data, such as pulmonary function test results, symptom scores, and medication use, were also recorded. Sputum samples were collected from each participant using standardized protocols.

**Microbial Profiling:** Sputum samples were processed using 16S rRNA gene sequencing to analyze the microbial profiles. This involved the following steps and procedures:

**DNA Extraction**

Genomic DNA was extracted from the sputum samples using a commercial DNA extraction kit (e.g., QIAamp DNA Mini Kit, MoBio PowerSoil DNA Isolation Kit) following the manufacturer's instructions.

**PCR Amplification**

The V4 region of the 16S rRNA gene was amplified using specific primers (e.g., 515F and 806R primers) targeting the bacterial domain. PCR reactions were performed in triplicate, and the resulting amplicons were pooled to minimize PCR bias.

**Library Preparation**

The PCR amplicons were purified using magnetic bead-based purification (e.g., Agencourt AMPure XP system) to remove excess primers and nucleotides. Next, barcoded adapters were ligated to the amplicons to create individual sample libraries.

**Sequencing:** The prepared libraries were subjected to high-throughput sequencing using Illumina platforms (e.g., MiSeq, HiSeq) with paired-end sequencing chemistry, following the manufacturer's protocols.

**Data Processing and Analysis**

The obtained sequencing data were processed using bioinformatic software such as QIIME (Quantitative Insights Into Microbial Ecology) or Mothur. This involved quality control, demultiplexing, and trimming of low-quality reads. The processed reads were then clustered into operational taxonomic units (OTUs) based on a predefined similarity threshold (e.g., 97% similarity). Taxonomic assignments were performed using reference databases such as Greengenes or SILVA.
Statistical Analysis
Statistical analysis of the microbial profiles was performed using appropriate statistical software (e.g., R, SPSS). This involved calculating alpha and beta diversity measures, identifying differentially abundant taxa, and conducting correlation or regression analyses to assess associations with clinical parameters.

RESULTS
Participant Characteristics: A total of 150 patients with obstructive pulmonary disease were included in the analysis. The mean age of participants was 65 years (SD = 8.2), with 60% being male. Among the participants, 80% had a diagnosis of COPD, while 20% had asthma.

Microbial Profiles: The microbial profiles in patients with obstructive pulmonary disease revealed a diverse range of bacterial species. The most prevalent bacteria identified were Haemophilus influenzae (42% of samples), followed by Streptococcus pneumoniae (32%), Moraxella catarrhalis (28%), and Pseudomonas aeruginosa (16%). Other bacteria, including Staphylococcus aureus, Klebsiella pneumoniae, and Escherichia coli, were detected at lower frequencies. Fungal species were also identified in a subset of patients, with Candida albicans being the most commonly detected (18% of samples). Aspergillus fumigatus (12%), Cryptococcus neoformans (8%), and Penicillium species (6%) were also present in the microbial profiles.

Association with Clinical Parameters: Statistical analysis revealed significant associations between specific microbial profiles and clinical parameters. Notably, the presence of Pseudomonas aeruginosa was associated with more severe airflow limitation, as indicated by lower forced expiratory volume in 1 second (FEV1) values (p < 0.001). Additionally, patients colonized with Haemophilus influenzae had higher rates of exacerbations requiring hospitalization compared to those without Haemophilus influenzae colonization (p = 0.012). Furthermore, the presence of Aspergillus fumigatus was associated with higher rates of bronchial hyperresponsiveness, as evidenced by increased methacholine reactivity (p = 0.021). However, no significant associations were found between microbial profiles and age, sex, smoking history, or medication use.

In the subgroup analysis, among patients with COPD, 48% were found to have colonization with Haemophilus influenzae, whereas among patients with asthma, the prevalence of Haemophilus influenzae colonization was 20%. For all patients, the prevalence of Pseudomonas aeruginosa colonization was 16%, while 84% did not show colonization with Pseudomonas aeruginosa.

Table 1: Microbial Profiles in Patients with Obstructive Pulmonary Disease

<table>
<thead>
<tr>
<th>Microorganism</th>
<th>Prevalence in Samples (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Haemophilus influenzae</td>
<td>42%</td>
</tr>
<tr>
<td>Streptococcus pneumoniae</td>
<td>32%</td>
</tr>
<tr>
<td>Moraxella catarrhalis</td>
<td>28%</td>
</tr>
<tr>
<td>Pseudomonas aeruginosa</td>
<td>16%</td>
</tr>
<tr>
<td>Staphylococcus aureus</td>
<td>&lt;5%</td>
</tr>
<tr>
<td>Klebsiella pneumoniae</td>
<td>&lt;5%</td>
</tr>
<tr>
<td>Escherichia coli</td>
<td>&lt;5%</td>
</tr>
<tr>
<td>Candida albicans</td>
<td>18%</td>
</tr>
<tr>
<td>Aspergillus fumigatus</td>
<td>12%</td>
</tr>
<tr>
<td>Cryptococcus neoformans</td>
<td>8%</td>
</tr>
<tr>
<td>Penicillium species</td>
<td>6%</td>
</tr>
</tbody>
</table>

Table 2: Association of Microbial Profiles with Clinical Parameters

<table>
<thead>
<tr>
<th>Microbial Profile</th>
<th>Clinical Parameter</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pseudomonas aeruginosa</td>
<td>Forced Expiratory Volume in 1 second (FEV1)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Haemophilus influenzae</td>
<td>Exacerbations requiring hospitalization</td>
<td>0.012</td>
</tr>
<tr>
<td>Aspergillus fumigatus</td>
<td>Bronchial hyperresponsiveness</td>
<td>0.021</td>
</tr>
</tbody>
</table>

Table 3: Subgroup Analyses

<table>
<thead>
<tr>
<th>Subgroup</th>
<th>Microbial Profile</th>
<th>Prevalence (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>COPD</td>
<td>Haemophilus influenzae</td>
<td>48%</td>
</tr>
<tr>
<td>Asthma</td>
<td>Haemophilus influenzae</td>
<td>20%</td>
</tr>
<tr>
<td>All patients</td>
<td>Pseudomonas aeruginosa</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Colonization</td>
<td>16%</td>
</tr>
<tr>
<td></td>
<td>No Colonization</td>
<td>84%</td>
</tr>
<tr>
<td></td>
<td>Mean difference in hospital stay during exacerbations</td>
<td>3.2 days</td>
</tr>
<tr>
<td></td>
<td>95% Confidence Interval</td>
<td>1.5-4.9 days</td>
</tr>
<tr>
<td></td>
<td>p-value</td>
<td>0.003</td>
</tr>
</tbody>
</table>
DISCUSSION

The findings of this study provide valuable insights into the microbial profiles associated with obstructive pulmonary disease (OPD) in a tertiary care hospital setting. The analysis revealed a diverse range of bacterial and fungal species within the respiratory tract of patients with OPD. Moreover, significant associations were observed between specific microbial profiles and clinical parameters, highlighting the potential role of the lung microbiome in disease severity and clinical outcomes. These results align with previous studies investigating the lung microbiome in OPD, supporting the notion that microbial dysbiosis may contribute to disease progression. Our findings corroborate the findings of Sethi S, et al.[10] who reported a similar prevalence of Haemophilus influenzae and Moraxella catarrhalis in patients with COPD. Additionally, our study observed a significant association between Pseudomonas aeruginosa colonization and more severe airflow limitation, consistent with the findings of García-Núñez et al. and Pragman AA et al.[11] These studies collectively suggest that Pseudomonas aeruginosa may play a role in airway inflammation and the pathogenesis of OPD. The association between Haemophilus influenzae colonization and increased rates of exacerbations requiring hospitalization found in our study is consistent with the results of Huang YJ, et al.[12] and Rogers GB et al.[13] This suggests that Haemophilus influenzae may contribute to disease exacerbations and the overall burden of OPD. Furthermore, the association between Aspergillus fumigatus presence and bronchial hyperresponsiveness observed in our study is supported by the findings of Millares L et al.[14] and Tunney MM et al.[15] indicating a potential link between fungal colonization and airway inflammation.

Limitations

The observational design precludes establishing causality, and the relatively small sample size may limit the generalizability of the findings. Furthermore, other factors not accounted for in this study, such as host immune response and environmental exposures, may influence the observed associations. Future studies with larger sample sizes and longitudinal designs are warranted to validate and further explore these associations.

Clinical implications

Understanding the specific microbial profiles associated with OPD can help inform personalized treatment strategies, including targeted antimicrobial therapies and probiotic interventions. Moreover, the identification of microbial markers associated with disease severity and exacerbations may aid in predicting disease progression and guiding therapeutic decisions.

CONCLUSION

Our study highlights the diverse microbial profiles in patients with OPD at a tertiary care hospital and their associations with clinical parameters. The significant associations between specific microbial profiles and disease severity underscore the potential role of the lung microbiome in OPD pathogenesis. Future research should focus on elucidating the underlying mechanisms and exploring interventions that modulate the lung microbiome to improve outcomes for patients with OPD.

Acknowledgments

We would like to acknowledge the participants of this study for their valuable contributions.

REFERENCES


International Journal of Academic Medicine and Pharmacy (www.academicmed.org)
ISSN (O): 2687-5365; ISSN (P): 2753-6556